Williamb Schultz News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Williamb schultz. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Williamb Schultz Today - Breaking & Trending Today

CBS Airs NSA Propaganda Informercial Masquerading As 'Hard Hitting' 60 Minutes Journalism By Reporter With Massive Conflict Of Interest

Last night I started seeing a bunch of folks on Twitter absolutely trashing 60 Minutes. We had mentioned last week that 60 Minutes would be doing something about the NSA, including the revelation that some NSA officials favored granting Snowden asylum, and that Keith Alexander ridiculously stated that people should be held accountable for their… ....

United States , White House , District Of Columbia , Ben Sherwood , Williamb Schultz , David Axelrod , Sari Horwitz , David Rhodes , Tom Nides , Shailagh Murray , Stephen Barr , Ari Shapiro , David Plouffe , Michael Gottlieb , Neil King , Justice Department , Department Of Human Services , Labor Department , Washington Post , Obama Administration , Tea Party , Big Govt , Big Govt Programs , President David Rhodes , President Ben Sherwood , President Obama ,

Oswego man accused of threatening state troopers

OSWEGO –- An Oswego man is accused of calling the regional headquarters of the New York State Police and threatening to harm a dispatcher and a trooper. ....

New York , United States , Williamb Schultz , York State Police , New York State Police ,

How an Unproven Alzheimer's Drug Got Approved - The New York Times


How an Unproven Alzheimer’s Drug Got Approved
Though some of its own senior officials said there was little evidence of benefit for patients, the F.D.A. nonetheless greenlighted Biogen’s Aduhelm, or aducanumab.
The F.D.A. conducted an internal inquiry this year after allegations were made that the agency was collaborating too closely with Biogen, maker of the Alzheimer’s drug Aduhelm.Credit.Andrew Kelly/Reuters
Published July 19, 2021Updated July 20, 2021, 9:29 a.m. ET
Two months before the Food and Drug Administration’s deadline to decide whether to approve Biogen’s controversial Alzheimer’s drug, aducanumab, a council of senior agency officials resoundingly agreed that there wasn’t enough evidence it worked. ....

New York , United States , Samantha Budd Haeberlein , Janet Woodcock , Rick Pazdur , Billy Dunn , Vissia Viglietta , Priya Singhal , Williamb Schultz , Maria Carrillo , Al Sandrock , Patrizia Cavazzoni , Michael Felberbaum , Budd Haeberlein , Wayne Pines , New York Times , Program Review Council , Department Of Health , Human Services , Drug Administration , Alzheimer Association , American Neurological Association , Drug Approved , New Drug , Public Citizen , Drug Evaluation ,